Market Overview

Benzinga's Top Upgrades

Benzinga's Top Upgrades
5 Biotech Stocks On Deck With The FDA
Sell The News In Sarepta Therapeutics
Several Biotech Stocks Indicating A Macro Short Strategy (Seeking Alpha)
Related PPO
Earnings Scheduled For March 4, 2015
Benzinga's Top Downgrades

Analysts at Goldman Sachs upgraded Team Health Holdings (NYSE: TMH) from “neutral” to “conviction buy.” The target price for Team Health has been raised from $33 to $43. Team Health's stock closed at $36.75 yesterday.

Analysts at Topeka Capital upgraded Polypore International (NYSE: PPO) from “hold” to “buy.” The target price for Polypore has been raised from $37 to $46. Polypore's shares closed at $39.13 yesterday.

JP Morgan upgraded CenturyLink (NYSE: CTL) from “neutral” to “overweight.” The target price for CenturyLink is set to $38. CenturyLink's shares closed at $35.06 yesterday.

Jefferies upgraded Ulta Salon, Cosmetics & Fragrance (NASDAQ: ULTA) from “hold” to “buy.” The target price for Ulta Salon has been raised from $85 to $100. Ulta Salon's shares closed at $82.00 yesterday.

Posted-In: top upgradesUpgrades Analyst Ratings


Related Articles (CTL + PPO)

Around the Web, We're Loving...

Get Benzinga's Newsletters